News Releases

Pharming Group N.V. today announces that the European Commission has granted orphan drug designation for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European

Pharming Group N.V. today announced positive data from a clinical trial with the use of RUCONEST® [Recombinant Human C1 Esterase Inhibitor/ conestat alfa] for the treatment of hereditary angioedema (HAE) attacks in children. RUCONEST® provided clinically meaningful relief of symptoms in children

Pharming Group N.V. today announces the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use programme of five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia that were treated with RUCONEST®

Pharming Group N.V. announces that the first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with RUCONEST® (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised

Pharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2020. Highlights: Delivered 14% increase in revenue, 31% increase in operating profit and, 33% increase in net profit year-on-year

Pharming Group N.V. announces the nomination of Barbara Yanni and Mark Pykett to its Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, the proposals related to remuneration were withdrawn and all other proposals were approved.

Pharming Group N.V. today supports “hae-day :-)”, the global awareness day for hereditary angioedema (HAE), a rare life-threatening condition.

Pharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2020. Highlights:  Delivered revenues of €49.3 million, an increase of 40% on Q1 2019  Operating profit of €19.4 million, an increase of 59% on Q1 2019 Despite significant one- off

Pharming Group N.V. announces that it has received formal European Commission approval to treat acute hereditary angioedema (HAE) attacks in children with RUCONEST®. Following the positive opinion and recommendation from the European Medicine Agency’s (EMA) Committee for Medicinal Products for